Riskpilot← Back to searchSign inGet full accessAiKang Medicine AB
ABActiveOrg 5569977985Hällbygatan 14Physiotherapy activities · NACE 8695Est. 20140 employees
Revenue 2024
—
EBITDA margin
—
Equity ratio
—
Financial strength
Net profit 2024
—
0 employees
| Revenue | — | — |
| EBITDA | SEK 0 | — |
| Net profit | — | — |
| Total assets | — | — |
| Equity | — | — |
| Employees | 0 | — |
Legal name
AiKang Medicine AB
Org number
5569977985
Legal form
Aktiebolag
NACE code
8695 · Physiotherapy activities
Founded
22 december 2014
Share capital
SEK 0
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska bedriva verksamhet inom utbildning av traditionell kinesisk medicin, bedriva traditionell kinesisk akupunkturklinik, import och export av medicinska instrument och hälsokost, tillverkning av hälsokost samt därmed förenlig verksamhet.
Address
Hällbygatan 14
Email
juanjia1979@yahoo.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 646 | — | — | — | — |
| Staff expenses | — | — | — | — | — |
| EBITDA | 115 | 0 | 0 | 0 | 0 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | 115 | 0 | 0 | 0 | 0 |
| Net financials | −1 | — | — | — | — |
| Profit before tax | 114 | 0 | 0 | 0 | 0 |
| Tax | −5 | — | — | — | — |
| Net profit | 109 | — | — | — | — |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 717 | — | — | — | — |
| Equity | 326 | — | — | — | — |
| Long-term debt | 170 | — | — | — | — |
| Short-term debt | 1 221 | — | — | — | — |
| Total debt | 1 391 | — | — | — | — |
EBITDA margin
0.0%
This company
15.8%
Market median
-100% vs market
20202024
Equity ratio
0.0%
This company
38.2%
Market median
-100% vs market
20202024
Return on equity
0.0%
This company
18.4%
Market median
-100% vs market
20202024
Net profit margin
0.0%
This company
8.1%
Market median
-100% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
-1.00×
This company
0.62×
Market median
+261% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
JJ Chief Executive Officer | Chief Executive Officer | 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2021 | |
| Former (1) | ||
| Chairman | 2021 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of AiKang Medicine AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Juan Jia | Chief Executive Officer | 0 companies |
| Kurt Karlsson | Deputy Board Member | 0 companies |
| Zhifen Pan | Chairman | 0 companies |